<DOC>
	<DOCNO>NCT02289560</DOCNO>
	<brief_summary>The objective prospective , multi site , single-arm study capture efficacy treatment use ExAblate Transcranial System demonstrate safety medication-refractory tremor patient essential tremor ( ET ) .</brief_summary>
	<brief_title>Continued Access Protocol : ExAblate Transcranial MR Guided Focused Ultrasound Treatment Essential Tremors</brief_title>
	<detailed_description>This study evaluate new technique perform Thalamotomy tremor control . While current technique possible invasive radiation effect , use ExAblate totally non-invasive without radiation . After informed consent screening , eligible subject undergo ExAblate treatment . All subject follow 1 day , 1 week , 1 , 3 , 6 12 month 5 year direct doctor .</detailed_description>
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Essential Tremor</mesh_term>
	<criteria>Men woman , age 22 year old Subjects able willing give inform consent able attend study visit Subjects diagnosis Essential Tremor confirm clinical history examination neurologist neurosurgeon specialize movement disorder Subject exhibit significant disability ET despite medical treatment Subjects stable dose ET medication 30 day prior study entry Subject able communicate sensation ExAblate Transcranial procedure Subjects unstable cardiac status Severe hypertension Subjects standard contraindication MR image nonMRI compatible implant metallic device include cardiac pacemaker , size limitation , etc . Known intolerance allergy MRI contrast agent include advanced kidney disease severely impaired renal function Significant claustrophobia manage mild medication Current medical condition result abnormal bleeding and/or coagulopathy Receiving anticoagulant ( e.g . warfarin ) antiplatelet ( e.g . aspirin ) therapy within one week focus ultrasound procedure drug know increase risk hemorrhage History intracranial hemorrhage History multiple stroke , stroke within past 6 month Subjects able willing tolerate require prolonged stationary supine position treatment Are participate participate another clinical trial last 30 day Subjects unable communicate investigator staff Subjects history seizure within past year Subjects brain tumor</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>